The presence of hypertension among the population with human immunodeficiency virus (HIV) has
become a new threat to the health and well-being of people living with this disease, in particular, among those
who received antiretroviral therapy. The estimated prevalence of high blood pressure in HIV‐infected patients is
significantly higher than the rate observed in HIV‐uninfected subjects. The approach to the HIV-positive patient
requires the assessment of individual cardiovascular risk and its consideration when designing the individualized
target. On the other hand, the numerous pharmacological interactions of antiretroviral (ARV) drugs are essential
elements to take into account. Serum levels of any kind of antihypertensive drugs may be influenced by
the coadministration of protease inhibitors, non-nucleoside reverse transcriptase inhibitor, or other antiretroviral.
Similarly, plasma concentrations of antiretroviral drugs can be increased by the concomitant use of calcium
channel blockers or diuretics. In this regard, the treatment of high blood pressure in HIV patients should be preferentially
based on ACE inhibitors or thiazide/thiazide-like diuretics or their combination.
Keywords: Antiretroviral, hypertension, antihypertensive treatment, HIV infection, interactions, cardiovascular disease.
Rights & PermissionsPrintExport